Overactive Bladder Awareness Tool Research Articles

Treatment of overactive bladder symptoms in women with Diunorm®: preliminary results report

Introduction. Overactive bladder (OAB) with or without urgent incontinence tends to progress with age and occurs in both men and women. However, the frequency of occurrence in the female population averages about 25%.Purpose of the study. To assess the effectiveness and safety of the drug Diunorm® (in caps.) in the prevention and treatment of OAB in women.Materials and methods. The statistical analysis includes the results of a survey of 28 women with symptoms of OAB, whose average age was 35.3 years. The drug Diunorm® was used for treatment in dosage 400 mg QD for 90 days. Patients completed the Overactive Bladder Awareness Tool and a urination diary. Additionally, urinalysis, bacteriological examination of urine, uroflowmetry, bladder ultrasound and cystoscopy were performed.Results. All women throughout the study had negative urine cultures and no pyuria in urinalysis, which excluded an infectious etiology of urinary dysfunction. During therapy, a statistically significant decrease in irritative symptoms was recorded according to the Overactive Bladder Awareness Tool questionnaire. The sum of points after 1 and 3 mo decreased by 3.0 and 4.3 points, respectively (p < 0.05). Positive dynamics in terms of the points' sum was noted in 75%, in relation to nocturia in 82% of patients (p < 0.01). The average urination rate increased from 13.3 ± 0.7 ml/s to 15.1 ± 0.7 ml/s and 15.4 ± 0.5 ml/s after 1.5 and 3 months, respectively (p < 0,0001). A similar trend was observed for maximum urine flow and residual urine volume. The maximum urine flow when taking Diunorm® increased from 15.9 ± 0.6 ml/s to 17.4 ± 0.5 ml/s and 18.1 ± 0.4 ml/s (p < 0.001). Residual urine volume decreased throughout the study. When included in the study, after 1,5 and 3 mo, this indicator was 19.9 ± 1.4; 12.2 ± 1.6 and 6.4 ± 1.1 ml, respectively (p < 0.001).Conclusion. Diunorm® can become a worthy alternative to traditional first-line OAB therapy. Comparative studies are required to obtain a high-level evidence base.

A prediction model for detrusor overactivity at ambulatory urodynamics in women with urinary incontinence

Objective(s)To develop a multivariable model using both clinical examination findings and validated questionnaires’ scores for predicting the presence of detrusor overactivity observed during ambulatory urodynamic monitoring in women with urinary incontinence. Study DesignThe study population was chosen from a registry of women evaluated with urodynamics for urinary incontinence retrospectively. Data for baseline characteristics, clinical findings, and ambulatory urodynamic records were evaluated for all women included to the study. Urodynamic data were obtained by retrospective review of urodynamic traces with a standardized protocol during single voiding cycle, compatible to the standards of International Continence Society (ICS) for ambulatory urodynamic monitoring. ResultsA total of 395 women with urinary incontinence were included in the study. Detrusor overactivity was diagnosed in 57.1% of women included to the study. Clinical factors positively associated with detrusor overactivity were higher body-mass index (OR = 1.10; 95% CI 1.03−1.15, p < 0.001), higher OAB-V8 (Overactive bladder awareness tool - version 8) scores (OR = 1.04; 95% CI 1.01−1.06, p < 0.001) and presence of urgency urinary incontinence (OR = 2.39; 95% CI 1.47−3.81, p < 0.001). The presence of postural urinary incontinence (OR = 0.51; 95%CI 0.28−0.90, p = 0.021) and insensible loss of urine (OR = 0.33; 95%CI 0.27−0.93, p = 0.005) had negative associations with detrusor overactivity in the final multivariate logistic regression analysis. Conclusion(s)BMI, OAB-V8 scores, urgency urinary incontinence, postural urinary incontinence and insensible loss of urine were associated with the presence of detrusor overactivity according to our prediction model. However, the overall model accuracy suggests urodynamic studies are still needed for a definitive diagnosis. Nevertheless, the prediction may be beneficial for selecting a subgroup of women who are unlikely to benefit from ambulatory urodynamic monitoring for the diagnosis of detrusor overactivity.

The effect of overactive bladder treatment with anticholinergics on female sexual function in women: a prospective observational study.

The aim of the study was to determine the effect of anticholinergics used for overactive bladder treatment on the sexual function of women. Between January 2016 and August 2018, over 18years old, 216 sexual active women with OAB and 165 healthy women as control group were prospectively enrolled in the study. Five different anticholinergics were used for the treatment. Female Sexual Function Index (FSFI), eight-item overactive bladder awareness tool (OAB-V8), and Beck Depression Inventory form were completed before and after 3months. Baseline and post-treatment scores were compared with a control group of age-matched healthy women. Patients with OAB reported at baseline significantly worse sexual function in all FSFI domains compared to healthy control group (21.47 ± 3.22 vs. 26.79 ± 5.56, p < 0.01). Three months after treatment, over 85% of participants reported clinically relevant improvements in sexual function, with statistically significant changes in mean FSFI scores. Treatment of OAB with anticholinergics can improve sexual function of sexual active women with OAB. Patients may be informed about this potential benefit of anticholinergic treatment, to improve their sexual function.

Screening for Urinary Incontinence in Women: A Systematic Review for the Women's Preventive Services Initiative.

Urinary incontinence is infrequently addressed during routine health care despite its high prevalence and adverse effects on health. To evaluate whether screening for urinary incontinence in women not previously diagnosed improves outcomes (symptoms, quality of life, and function) and to evaluate the accuracy of screening methods and potential harms of screening. English-language searches of Ovid MEDLINE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews (1 January 1996 to 30 March 2018); ClinicalTrials.gov (April 2018); and reference lists of studies and reviews. Randomized trials, cohort studies, systematic reviews of studies that enrolled nonpregnant women without previously diagnosed urinary incontinence and compared clinical outcomes and adverse effects between women who were and were not screened, and diagnostic accuracy studies that reported performance measures of screening tests. Dual extraction and quality assessment of individual studies. No studies evaluated the overall effectiveness or harms of screening. Seventeen studies evaluated the diagnostic accuracy of 18 screening questionnaires against a clinical diagnosis or results of diagnostic tests. Of these, 14 poor-quality studies were based in referral clinics, enrolled only symptomatic women, or had other limitations. One good-quality and 2 fair-quality studies (evaluating 4 methods) enrolled women not recruited on the basis of symptoms. Areas under the receiver-operating characteristic curve for stress, urge, and any type of incontinence in these studies were 0.79, 0.88, and 0.88 for the Michigan Incontinence Symptom Index; 0.85, 0.83, and 0.87 for the Bladder Control Self-Assessment Questionnaire; and 0.68, 0.82, and 0.75 for the Overactive Bladder Awareness Tool. The Incontinence Screening Questionnaire had a sensitivity of 66% and specificity of 80% for any type of incontinence. Studies enrolled few participants, often from symptomatic referral populations; used various reference standards; and infrequently reported CIs. Evidence is insufficient on the overall effectiveness and harms of screening for urinary incontinence in women. Limited evidence in general populations suggests fairly high accuracy for some screening methods. Health Resources and Services Administration.

Anatomical and Functional Results of Pelvic Organ Prolapse Mesh Repair: A Prospective Study of 105 Cases

Objective: We assess the anatomical and functional results of pelvic organ prolapse (POP) repair with application of transvaginal synthetic meshes. Keywords: pelvic organ prolapse, vaginal repair, urogynecology. Methods: We analyzed a cohort of 105 women who underwent transvaginal pelvic floor repair using mesh (Elevate Prolapse Repair System). A gynecological examination, cough test, uroflowmetry and an administration of the overactive bladder Awareness Tool were done. Parametric and nonparametric methods of descriptive statistics, as well as logistic regression were used for data analysis. Results: Prolapse recurrence after vaginal repair was noted in 3.81% (n=4) of patients. The proportion of patients with de novo onset of incontinence after surgery was 8.57% (n=9). In 26.7% (n=28) of women with stress urinary incontinence (SUI), SUI symptoms persisted after surgery. The mean Qmax in the patient group was 19.5 ml/s. The mean Qmax in patients reporting bladder-emptying problems was 14 ml/s, and the mean post-void residual (PVR) was 50±15.0 ml. After surgery, the mean Qmax increased to 27.6 ml/s. The PVR after surgery decreased to 30±5.0 ml. The number of patients with bladder outlet obstruction symptoms decreased to 17 (16.19%). Conclusion: The management of genital prolapse with synthetic prostheses interposed through vaginal approach is an efficient method with good midterm outcomes.

Factors associated with overactive bladder syndrome in the elderly community: a cross-sectional study

Abstract Objective: to identify risk factors related to overactive bladder syndrome. Method: a cross-sectional study was performed with elderly women (&gt;60 years) from the community of Ceilândia, in the Distrito Federal, Brazil, with or without symptoms of OBS, who were evaluated through interviews and questionnaires. The clinical and sociodemographic variables analyzed were: age; body mass index (BMI); parity, schooling, previous abdominal and urogynecologic surgeries, physical activity, smoking, constipation, systemic arterial hypertension (SAH), diabetes mellitus; depression and anxiety. The questionnaires applied were the Overactive Bladder Awareness Tool (OAB-V8), the Geriatric Depression Scale and the Beck Anxiety Scale. Data were analyzed descriptively. Binary logistic regression was used to evaluate the significant associations between the independent variables and the outcome of interest. Risk ratios were calculated for each independent variable with 95% confidence intervals. Result: A total of 372 volunteers were recruited, 292 of whom were eligible. Of these, 172 were allocated to the case group (58.9%) and 120 (41.1%) were control subjects. The two groups were homogeneous between one another. There was a high prevalence of OBS in the study population and significant differences for the variables presence of SAH, abdominal surgery and pelvic surgery, with the case group presenting a higher frequency of these events. In multivariate analysis, it was observed that an active sexual life reduces the chance of having OBS by 70.8%, while urogynecologic surgeries increase this risk 3.098 times. Conclusion: In univariate logistic regression analysis, BMI, SAH, a previous history of abdominal and urogynecologic surgery, number of abortions and the presence of symptoms of depression and anxiety, were found to be factors associated with OBS.

Prevalencia y caracterización de la vejiga hiperactiva detectada en una población de Madrid con el cuestionario OAB-V3 autoadministrado en atención primaria

ObjectiveDetermining the prevalence of symptoms suggestive of overactive bladder (OAB) in a Spanish population and evaluate the impact of these symptoms on well-being and labour productivity in this population. DesignTransversal study. LocationPrimary health care, Madrid, Spain. ParticipantsMales and females >30 years. InterventionsClassification by primary care physicians with the Overactive Bladder Awareness Tool abbreviated version (OAB-V3). Subjects with score ≥3 and a similarly balanced control population with score <3 were clinically investigated. Principal measurementsHistory, physical examination, urinalysis, sonography, general well-being scale and the questionnaires PPBC, OAB-q y WPAI-SHP. ResultsA total 923 subjects were screened, of which 209 (22.6%), 35% males and 65% females, had probable OAB. Age distribution increased from 11.1% in 4th decade to 44.4% in 9th decade. Kappa coefficient between suspected OAB and definite diagnosis was .83. The area under ROC curve for diagnosis based on OAB-V3 questionnaire and the presence of perceived bother and coping strategies was 92%. Subjects classified by score ≥3 had worse well-being, higher PPBC score and worse parameters on total OAB-q and transformed scores for each OAB-q subscale (P<.0001). In these subjects labour productivity was not affected (P=.14) but the capacity to perform regular activities was (P<.0001). ConclusionsOAB-V3 is a simple questionnaire to screen OAB with good predictive accuracy in a primary care setting and reveals important implications on health related quality of life issues.

Ambulatory urodynamic monitoring of women with overactive bladder syndrome during single voiding cycle

Objective(s)To present data of standardized ambulatory urodynamic monitoring (AUM) performed in women with overactive bladder syndrome (OAB) and to evaluate the relevance of AUM data with clinical findings of the patients. Study designRecords of women with symptoms of OAB were retrospectively reviewed (n=249). Of women fulfilling the Overactive Bladder Awareness Tool (OAB-V8) with a score ≥8 and the 3-day voiding diary (VD) with a frequency >7/day (n=167), those who underwent urodynamic investigation were selected (n=76). The data of this study were retrieved from the records of Ankara University Cebeci Hospital and based on the AUM findings of single voiding cycle of women with OAB. AUM, which is among the institutionally approved primary urodynamic investigation methods, is performed with LUNA ambulatory monitoring recorder (MMS™) in the clinical setting with a standardized technique, in reproducing lower urinary tract symptoms of women since 2011. The relationship of the urodynamic data with the clinical findings were evaluated. ResultsAUM traces of women (n=76) with OAB revealed 63.1% DO, 64.4% urgency and 77.7% urinary incontinence of which were 14.4% urgency urinary incontinence (UUI), 25% stress urinary incontinence (SUI) and 38.1% mixed urinary incontinence (MUI). OAB patients with DO reported more urinary incontinence episodes/day, nocturia and mixed urinary incontinence in the voiding diary (p<0.04) and had significantly higher irritative symptom bother reflected by the questionnaires (p<0.04). Women with DO were more likely to be postmenopausal (p=0.02) and were found to have more urgency (p<0.001), urgency episodes (p=0.05) and incontinence (urge and mixed) (p<0.001). However, no association was found between the extent of pelvic organ prolapse and the presence of DO. ConclusionsAUM performed with a standardized technique during single voiding cycle seems to be a reliable method in reproducing symptoms of women with OAB. It provides both clinically relevant findings and objective documentation of urgency which is the main symptom for OAB. The detection of DO according to the ICS definition were also found to be concordant with urodynamicaly observed urgency and urinary incontinence. Objective and subjective clinical findings of OAB were found to be more severe in women with DO.

Potential benefits of diagnosis and treatment on health outcomes among elderly people with symptoms of overactive bladder.

SummaryObjectivesThis study examined potential benefits of diagnosing and treating elderly adults with overactive bladder (OAB) symptoms.MethodsData were analysed from the OAB Re‐Contact Study (N = 2750), a cross‐sectional, self‐reported Internet survey. Elderly respondents (65+ years old) with OAB were identified according to current medication use to control OAB symptoms or by scores > 14 (men) or > 16 (women) on the OAB Awareness Tool. Treated were those currently using prescription medication and never treated were those who never used prescription medication for OAB. Outcome measures included health‐related quality of life, activity impairment, OAB‐related severity and symptoms, and healthcare resource use (e.g. hospitalisations). Generalised linear models predicted health outcomes as a function of diagnosis or treatment, adjusting for covariates.ResultsDiagnosed vs. not diagnosed elderly respondents had higher mental component summary (MCS) scores and SF‐6D health utilities, and less activity impairment. Treated vs. never treated elderly respondents had higher MCS and SF‐6D health utilities, less activity impairment, fewer OAB symptoms, lower OAB Awareness Tool scores, and lower odds of having bladder problems or incontinence. There were no significant differences in healthcare resource use. Further analysis by age group (middle‐aged vs. elderly respondents) revealed significantly greater diagnosis‐ and treatment‐related benefits on MCS (2.93 and 4.49 points more, respectively) and activity impairment (1.24 and 1.37 times as much, respectively) among elderly respondents.ConclusionsDiagnosis and treatment were each associated with a lower health burden for elderly adults with OAB symptoms. These findings highlighted the importance of diagnosis and treatment in alleviating OAB symptoms and their impact on health outcomes.

A prospective randomized trial comparing the use of tolterodine or weighted vaginal cones in women with overactive bladder syndrome

ObjectiveTo compare the efficacy of pelvic floor muscle exercises (PFME) using weighted vaginal cones (WVC) on the symptoms, clinical findings, urodynamic findings and quality of life (QoL) in overactive bladder (OAB) patients with tolterodine. Study designThirty-nine patients with urinary frequency (≥8/day), nocturia (≥2/night), urgency and a total score of ≥8 to the overactive bladder-awareness tool (OAB-V8) were diagnosed as OAB and were randomized into two treatment groups; WVC and extended release tolterodine (tolterodine ER) 4mg/day for 8 weeks. Results of the clinical findings, 3-day urinary diary, validated questionnaires for symptom bother and QoL (Urinary distress inventory (UDI-6), incontinence impact questionnaire (IIQ-7), OAB-V8, Wagner questionnaire) and urodynamic examination before and after treatment were compared. ResultsA reduction of frequency, nocturia and urinary incontinence was observed in WVC group (p=0.006, p=0.034 and p=0.008, respectively) and in tolterodine group (p<0.001, p=0.002 and p=0.035, respectively). 24-h dry pad test results were improved significantly in both groups (p=0.003 and p=0.001, respectively). Pelvic muscle strength was significantly improved in WVC group but not in tolterodine group (p=0.010 and p=0.180, respectively). UDI-6, IIQ-7, OAB-V8 scores were improved significantly in both groups. Improvements in Wagner questionnaire were observed in WVC group but not in tolterodine group (p=0.002 and p=0.591, respectively). First sensation of bladder filling was significantly improved after WVC treatment but not in tolterodine group (p=0.035 and p=0.550, respectively). After treatment, detrusor overactivity (DO) resolved in 8 patients in the WVC group (p=0.003) and in 2 patients in the tolterodine group (p=0.426). ConclusionsWVC treatment seems to be an efficacious therapeutic option for the improvement of overactive bladder syndrome (OABS).

Urinary nerve growth factor and a variable solifenacin dosage in patients with an overactive bladder

We evaluated changes in urinary nerve growth factor (NGF) and NGF/creatinine (NGF/Cr) levels after increasing the dosage of solifenacin in overactive bladder patients. The study groups included 59 overactive bladder (OAB) patients and 20 healthy subjects as controls. We measured NGF at baseline for the patients and controls, and used the Overactive Bladder Awareness Tool (OAB-V8) to evaluate urinary symptoms. All patients received a treatment of solifenacin 5 mg for 6 weeks. The responders to treatment served as group 1 and nonresponders received solifenacin 10 mg for an additional 6 weeks. Responders and nonresponders to the 10-mg treatment were defined as groups 2 and 3 respectively. NGF was measured after each treatment using the ELISA method and normalized by the urinary creatinine levels (NGF/Cr). There were 21, 22 and 16 patients in groups 1, 2, and 3 respectively. At baseline, the NGF and NGF/Cr levels were higher in groups 1, 2, and 3 compared with the controls. After the solifenacin 5 mg treatment, the NGF and NGF/Cr levels of group 1 individuals decreased to those of the control level. After increasing the dosage of solifenacin to 10 mg in group 2, the NGF and NGF/Cr levels decreased to normal levels. In group 3 (patients who did not responded to any treatment), these levels remained unchanged. Our results suggest that urinary NGF could be a potential biomarker for monitoring the treatment of symptoms in OAB patients who are treated with solifenacin.

Validación psicométrica de las escalas OAB-V8 y OAB-V3 para la detección de pacientes con probable vejiga hiperactiva en la población española

Background and objectiveTo perform the psychometric validation in the Spanish population of the Overactive Bladder Awareness Tool (OAB-V8) scale and its abbreviated version OAB-V3 for screening patients with probable overactive bladder (OAB). Patients and methodsA cross-sectional study was conducted in a population aged over 18 years, which was representative of the prevalence of OAB in Spain using an online methodology (Internet survey). Psychometric properties included feasibility, reliability, and validity. Subjects were classified according to the likelihood of OAB, using an automated algorithm validated previously. ROC curve analysis was performed, and the sensitivity, specificity, and positive and negative predictive values were also assessed. ResultsA total of 2,035 subjects with a mean+SD age of 52.7+12.1 years were included (50.8%) men. In total 13.7% were classified as «Probable», 27.9% «Possible», and 58.3% «No» OAB. The internal consistency of both OAB-V8 and OAB-V3 scales was high (0.894 and 0.851, respectively). The item-total correlation coefficients were high; 0.87-0.88 and 0.71-0.83, respectively. Intraclass correlation coefficient for OAB-V8 was 0.826 (confidence interval 95% 0.695-0.901) and it was 0.828 (confidence interval 0.623-0.922) for OAB-V3. The optimum cut-off value of OAB-V8 for detecting probable OAB was≥8 points (AUC=0.895, sensitivity 0.875, specificity 0.735), while for the OAB-V3 it was ≥ 3 (AUC=0.910, sensitivity 0.828, specificity 0.825). ConclusionBoth OAB-V8 and OAB-V3 scales were considered useful online self-administered screening tools, which were also feasible, reliable and valid for the detection of patients with probable OAB in the general population in Spain.

The multidimensional sensation of desire to void differs between people with and without overactive bladder

To determine whether the multidimensional sensation of desire to void can be reliability assessed and whether differences exist between people with and without overactive bladder (OAB). Assessing reliability and convergent validity of OAB screening tools comprised a secondary aim. This observational, repeated-measures study involved 64 volunteers (47 female), aged ≥50 years, with and without OAB symptoms. Six sensory dimensions (intensity, unpleasantness, suddenness, perceived difficulty "holding on," bladder fullness and location of sensation) were assessed by structured interview on two occasions. Overactive bladder status was determined using the OAB Symptom Score and OAB Awareness Tool. Reliability of sensory dimensions was assessed via random effects mixed modeling. The ability of each sensory dimension to predict OAB status was determined by partial least squares regression. With the exception of sensory intensity, perceived bladder fullness, and one location of sensation, sensory dimensions were reliably reported. Sensory intensity, unpleasantness, suddenness, and perceived difficulty "holding on" predicted OAB, whereas perceived bladder fullness and sensory location did not. The OAB screening questionnaires demonstrated comparable test-retest reliability and convergent validity. People with and without OAB can reliably describe the multidimensional sensation of desire to void. The sensation of desire to void is more intense, unpleasant, sudden, and perceived as more difficult to hold on in people with OAB.

Descriptors of sensation confirm the multidimensional nature of desire to void

To collect and categorize descriptors of "desire to void" sensation, determine the reliability of descriptor categories and assess whether descriptor categories discriminate between people with and without symptoms of overactive bladder. This observational, repeated measures study involved 64 Australian volunteers (47 female), aged 50 years or more, with and without symptoms of overactive bladder. Descriptors of desire to void sensation were derived from a structured interview (conducted on two occasions, 1 week apart). Descriptors were recorded verbatim and categorized in a three-stage process. Overactive bladder status was determined by the Overactive Bladder Awareness Tool and the Overactive Bladder Symptom Score. McNemar's test assessed the reliability of descriptors volunteered between two occasions and Partial Least Squares Regression determined whether language categories discriminated according to overactive bladder status. Post hoc Chi squared analysis and relative risk calculation determined the size and direction of overactive bladder prediction. Thirteen language categories (Urgency, Fullness, Pressure, Tickle/tingle, Pain/ache, Heavy, Normal, Intense, Sudden, Annoying, Uncomfortable, Anxiety, and Unique somatic) encapsulated 344 descriptors of sensation. Descriptor categories were stable between two interviews. The categories "Urgency" and "Fullness" predicted overactive bladder status. Participants who volunteered "Urgency" descriptors were twice as likely to have overactive bladder and participants who volunteered "Fullness" descriptors were almost three times as likely not to have overactive bladder. The sensation of desire to void is reliably described over sessions separated by a week, the language used reflects multiple dimensions of sensation, and can predict overactive bladder status.

Overactive bladder and its effects on sexual dysfunction among women

To evaluate the relation between overactive bladder (OAB) and sexual dysfunction in sexually active nurses without stress urinary incontinence and pelvic organ prolapse. Prospective, observational study. Tertiary care center. 200 nurses, under 49 years of age. Data were obtained with Turkish language-validated questionnaires between January 2011 and June 2011. OAB was diagnosed using the Overactive Bladder Awareness Tool (OAB AT). Scores on the Overactive Bladder Symptom and Health-related Quality of Life Questionnaire Short Form (OABq-SF), the Health-related Quality of Life Questionnaire Short Form (HRQOL), and the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire Short Form (PISQ-12). Of the 127 enrolled volunteers, 51 were diagnosed with OAB. The mean age of the participants was 37.8 ± 7.3 years. After controlling for age, body mass index, and parity, OAB did not significantly affect PISQ-12 scores, but significantly worsened OABq-SF scores. No strong correlation was noted between the parts of the OABq-SF and the domains of the PISQ-12. OAB is a common problem among sexually active young women and significantly affects their quality of life. However, OAB-related sexual dysfunction plays a limited role among sexually active nurses.

Correlation of pelvic organ prolapse staging with lower urinary tract symptoms, sexual dysfunction, and quality of life

To evaluate the relationship between pelvic organ prolapse (POP) staging and clinical findings, lower urinary tract symptoms (LUTS), sexual dysfunction, and quality of life (QoL) using validated questionnaires. Women attending the urogynecology unit with LUTS and/or bulging (n = 388) were grouped according to the POP quantification (POPQ). LUTS, sexual dysfunction, and QoL were evaluated using the Urinary Distress Inventory-6 (UDI-6),the Overactive Bladder Awareness tool (OAB-V8), the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12), and the Incontinence Impact Questionnaire-7 (IIQ-7). Data regarding baseline characteristics, clinical findings, and scores of questionnaires were compared among the POP stages using the Kruskal-Wallis test. Pearson's and Spearman's correlation analyses were used to evaluate the correlation of POP staging with clinical findings, pelvic floor dysfunction related symptom severity, and QoL. According to the POPQ, patients were classified as: stage 0 (27.8 %), stage 1 (21.4%), stage 2 (38.9%), and stages 3 and 4 (11.8%). Irritative, stress, obstructive subscale scores of UDI-6 and physical, travel, emotional subscale scores of IIQ-7 were significantly different among POPQ stages. Weak correlations between POPQ staging and irritative, stress, obstructive subscale scores of UDI-6 (r = 0.198, r = 0.192, and r = 0.146 respectively), and physical, travel, social, emotional subscale scores of IIQ-7 (r = 0.223, r = 0.154, r = 120 and r = 0.171 respectively) were found (p < 0.05). Clinical findings (Q-tip and stress test positivity, post-void residual volumes) showed moderate to weak correlations with POPQ stages (r = 0.425, r = 0.117, r = 0.163 respectively; p < 0.05). The correlation of lower urinary tract dysfunction and POP staging was shown to be best represented by UDI-6 and IIQ-7.

PRM105 Predicting Subjective Antimuscarinic Effectiveness on Symptoms of Overactive Bladder Using the Eight-Item Overactive Bladder Awareness Tool (OAB-V8)

PRM105 Predicting Subjective Antimuscarinic Effectiveness on Symptoms of Overactive Bladder Using the Eight-Item Overactive Bladder Awareness Tool (OAB-V8)

A comparison study of two lower urinary tract symptoms screening tools in clinical practice: The B-SAQ and OAB-V8 questionnaires

Lower urinary tract symptoms (LUTS) have a detrimental effect on quality-of-life (QoL). However, sufferers are often reluctant to seek help. Screening for LUTS will identify patients with bothersome symptoms who may benefit from treatment and allow patients to self-assess their symptoms and the need for medical intervention, potentially saving costly medical time and reducing long-term morbidity. The aim of this study was to compare the value of two validated questionnaires: the Bladder Control Self Assessment Questionnaire (B-SAQ) and the Overactive Bladder Awareness Tool (OAB-V8) as screening questionnaires in clinical practice. A total of 223 women were recruited prospectively from three centres. Participants completed both questionnaires in the waiting area prior to assessment by a clinician, who completed a symptom evaluation sheet. Data were analysed using receiver operating characteristic curves. Both the B-SAQ and the OAB-V8 performed well in detecting symptoms of OAB and mixed urinary symptoms. The B-SAQ performed better in detecting symptoms of stress incontinence than the OAB-V8. The opportunity to screen for haematuria should never be missed and this is an important omission from the OAB-V8.

Validation of a 3-item OAB awareness tool

The purpose of this study was to validate a short awareness tool to assist patients in identifying if they have bothersome overactive bladder (OAB) symptoms. This secondary analysis study utilised data from a cross-sectional study of adult patients presenting for primary care visits. Patients completed an 8-item OAB screener. The clinician probed for urinary frequency, urgency, nocturia and urgency urinary incontinence. If the patient screened positive or reported the presence of at least one OAB symptom, additional questions were asked regarding lifestyle and coping issues. The clinician then diagnosed the patient as having No OAB, Possible OAB, or Probable OAB. Multivariate logistic regressions were performed to assess the feasibility of deriving a shorter screener to raise awareness of OAB among primary care patients. The 1,260 patients in this study were 51.6±17.0 years old; 62% were women; and most (89%) were Caucasian. Clinicians diagnosed 12.1% of patients with Probable OAB, 19.7% with Possible OAB and 68.3% with No OAB. The logistic regression models were performed with OAB clinical diagnosis as the dependent variable comparing No OAB versus Probable OAB. Three items which included the symptoms of urinary frequency, urinary urgency and urine loss associated with a strong desire to urinate performed well as an awareness tool. A cut-point of four provided the most appropriate sensitivity (82%) and specificity (91%) when identifying Probable OAB and yielded adequate model fit. The final 3-item OAB Awareness Tool (OAB-V3) is gender neutral. The 3-item OAB Awareness Tool (OAB-V3) correctly identified patients with symptoms of OAB with high sensitivity and specificity and can be used as a conversation starter for patients with symptoms of OAB.

Prevalence of probable overactive bladder in a private obstetrics and gynecology group practice

ABSTRACTObjective: To examine the prevalence of probable overactive bladder (OAB) in black, Hispanic, and white women.Research design and methods: This was a cross-sectional survey of women (aged ≥ 18 years) presenting to a private obstetrics and gynecology group practice. The survey consisted of the Overactive Bladder-Validated 8 (OAB-V8) and other questions related to ethnicity, health history, desire for treatment, and reason for visit.Main outcome measure: The OAB-V8 is a validated, eight-item, self-administered questionnaire that assesses the degree of bother associated with OAB symptoms. Subjects scoring ≥ 8 on the OAB-V8 were considered to have probable OAB.Results: A total of 947 women completed the OAB-V8: 82% were black, 10% were white, and 4% were Hispanic. The prevalence of probable OAB was similar among different races/ethnicities, with 35% of black, 36% of Hispanic, and 30% of white women scoring ≥ 8 on the OAB-V8. Micturition frequency, nocturia, and waking up at night were the most bothersome symptoms. History of constipation, history of urinary tract infection, and number of pregnancies were independent risk factors for probable OAB. Thirty-five percent of patients with probable OAB and 5% of those without OAB desired information about OAB treatment options; however, only 5% of patients reported visiting their doctor for reasons related to their bladder symptoms.Conclusions: OAB is prevalent among black, white, and Hispanic women. Using a simple OAB awareness tool, such as the OAB-V8, can help clinicians identify patients with bothersome OAB symptoms who could benefit from treatment. The survey results may have been limited by incorrect self-reported responses, the demographics of the population, and incomplete surveys.